Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients

Ionis Pharmaceuticals announced positive topline results from pivotal Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyc...
Home/KnloSights/Clinical Trial Updates/Olezarsen Shows Significant Reduction in Triglycerides and Acute Pancreatitis in sHTG Patients